Thermogenesis and mitochondrial uncoupling — how the body turns energy into heat

Thermogenesis is the production of heat by the body as a result of metabolic reactions. A particular form of it is mitochondrial uncoupling — a process in which the energy from the oxidation of nutrients is dissipated as heat rather than stored as ATP. This is the mechanism behind the action of brown adipose tissue and the UCP1 protein, and, in research pharmacology, behind the action of compounds such as BAM15 and SLU-PP-332.

This article is educational in nature and constitutes a review of the published scientific literature. Most of the studies cited on pharmacological uncouplers were conducted in animal models or in vitro. The text describes a biochemical mechanism, not use in humans.

What is thermogenesis — two types of heat production

Every metabolic reaction is energetically imperfect — some of the energy always escapes as heat. Physiology distinguishes two types of thermogenesis.

Obligatory thermogenesis is heat generated “incidentally” by basic life processes — an unavoidable by-product of resting metabolism. Adaptive (facultative) thermogenesis, by contrast, is heat production actively regulated in response to stimuli: cold, a meal, hormonal signals. It is this second type that is the subject of intensive research into energy metabolism, because the body can increase or decrease it.

At the heart of adaptive thermogenesis lies the phenomenon of mitochondrial uncoupling. To understand it, one must look at how a mitochondrion normally produces energy.

Mechanism: how a mitochondrion turns fuel into energy — and when it turns it into heat

A mitochondrion produces ATP, the cell’s universal energy currency, in the process of oxidative phosphorylation. This proceeds in two coupled stages.

In the first stage, the respiratory chain in the inner mitochondrial membrane oxidises electrons derived from nutrients and uses the released energy to pump protons (H⁺) out across the inner membrane. A proton gradient is created — a difference in concentration and charge on either side of the membrane, known as the proton-motive force. This is a kind of charged battery.

In the second stage, the protons return into the mitochondrion through the enzyme ATP synthase, and the energy of their flow drives the production of ATP. In a healthy, “coupled” mitochondrion the two stages are linked together: the oxidation of fuel drives the production of ATP.

Uncoupling consists in disconnecting these two stages. When protons leak back into the interior bypassing ATP synthase, the energy of the gradient is not captured in ATP — it is dissipated as heat. The mitochondrion still oxidises fuel, but instead of storing energy it produces heat. From the perspective of the energy balance, uncoupling increases energy expenditure: the body “burns” substrates without storing their energy.

It is worth noting that a certain degree of “proton leak” always occurs in mitochondria, even without specialised uncoupling proteins — it is estimated to account for a substantial part of resting oxygen consumption. Adaptive thermogenesis is, in essence, a regulated increase in this phenomenon. Uncoupling is therefore not so much a “defect” in energy production as a physiological mechanism in which the body deliberately lowers the efficiency of ATP generation in order to produce heat or increase energy turnover. This duality — efficiency versus heat production — underlies the interest in uncoupling in metabolic research.

Brown adipose tissue and the UCP1 protein — the physiological uncoupler

The natural, physiological example of uncoupling is brown adipose tissue (BAT — brown adipose tissue). Unlike white adipose tissue, which stores energy, brown tissue is specialised in dissipating it. Its cells are packed with mitochondria, whose high content of respiratory pigments gives the tissue its brown colour.

The key lies in the uncoupling protein UCP1 (thermogenin) present in these mitochondria. UCP1 is a channel that allows protons to return across the inner membrane bypassing ATP synthase — precisely the mechanism described above. Once activated (classically by cold, via the sympathetic nervous system and noradrenaline), UCP1 “dissipates” the proton gradient, and brown tissue begins to produce heat intensively at the expense of the oxidation of fatty acids and glucose.

In adult humans, the presence of active brown adipose tissue has been confirmed by imaging (PET) — particularly in the region of the neck and collarbones, activated by exposure to cold. This finding made uncoupling thermogenesis a hot topic in research into energy metabolism (Cannon and Nedergaard, 2004).

Beige adipocytes — browning of white tissue

The picture is complicated by what are known as beige (brite — brown-in-white) adipocytes. These are cells that arise within white adipose tissue and which, under the influence of appropriate stimuli — chronic exposure to cold, sympathetic activity, certain hormonal signals — acquire the characteristics of brown cells: they increase the number of mitochondria and the expression of UCP1. This process is referred to as the browning of white tissue.

Beige adipocytes are of particular interest because they raise the question of whether “switching” part of the storage adipose tissue to an energy-dissipating mode can be induced pharmacologically. This is one of the theoretical contexts for research into compounds affecting mitochondrial biogenesis and the oxidative metabolism of adipocytes — although the path from observation in an animal model to confirmation in humans remains a long one.

Pharmacological uncoupling — from DNP to targeted compounds

Since mitochondrial uncoupling increases energy expenditure, researchers have long analysed chemical compounds that induce this effect independently of UCP1.

1. 2,4-dinitrophenol (DNP) is the classic, non-selective uncoupler — a small molecule that itself carries protons across membranes, “dissipating” the gradient in mitochondria throughout the body. Historically studied in the 1930s, DNP proved extremely dangerous: it has a very narrow margin between the dose that produces an effect and the lethal dose, and uncontrolled uncoupling leads to dangerous hyperthermia. The problem is mechanistically unavoidable for a compound of this type: since DNP uncouples mitochondria throughout the body without any selectivity, there is no way to confine the effect to a safe level — at a slightly higher exposure, heat production escapes the control of thermoregulation. DNP is not a subject of rational metabolic pharmacology — it serves as a cautionary point of reference, illustrating why targeted uncouplers with a safer profile are being sought.
2. BAM15 is the subject of more recent research into mitochondrial uncouplers. Unlike DNP, BAM15 uncoupled mitochondria in animal models without depolarising the cell (plasma) membrane — which in the preclinical literature has been associated with a more favourable profile than classic protonophores (Kenwood et al., 2014). In mouse models of diet-induced obesity, reversal of weight gain and improved insulin sensitivity have been described (Alexopoulos et al., 2020; Axelrod et al., 2021). The data come from animal models; BAM15 remains a research reagent, with no confirmation of efficacy and safety in humans.
3. SLU-PP-332 acts by a different mechanism — it is not a direct uncoupler. It is an agonist of ERR receptors (estrogen-related receptors), transcription factors that regulate mitochondrial biogenesis and oxidative metabolism. Instead of dissipating the gradient in existing mitochondria, SLU-PP-332 increased their number and oxidative capacity in animal models — hence it is described as an “exercise mimetic”, mimicking part of the metabolic adaptations induced by endurance training (Billon et al., 2024). This is a separate route to increasing energy expenditure: more, and more efficient, “power plants” rather than dissipating the gradient in existing ones.

A comparison of these two compounds illustrates well that “increasing energy expenditure” is not a single mechanism but a family of distinct strategies. BAM15 represents the dissipation approach — it lowers the efficiency of existing mitochondria in order to release energy as heat. SLU-PP-332 represents the expansion approach — it increases the cell’s oxidative capacity through mitochondrial biogenesis. The first route increases energy losses in mitochondria that are already present; the second increases the cell’s ability to oxidise substrates. This distinction matters for the interpretation of studies: two compounds colloquially described as “speeding up the metabolism” act at entirely different levels of mitochondrial biology.

State of research — an overview

The common denominator is interpretive caution: the data on pharmacological uncouplers come almost exclusively from animal and cellular models. Their translation to human physiology remains the subject of research, not an established fact.

Research reagents in the area of thermogenesis

The mechanisms described above are the subject of laboratory research conducted using reagents with a defined mechanism of action. The One-Peptides catalogue offers two compounds relevant to this area:

• BAM15 (BAM15 25 mg) — a mitochondrial uncoupler analysed in models of energy metabolism.
• SLU-PP-332 (SLU-PP-332 500 mcg) — an ERR agonist / exercise mimetic, studied in the context of mitochondrial biogenesis.

Both are chemical reagents intended solely for laboratory research use (Research Use Only) — they are not medicines, supplements or products for use in humans. A fuller picture of the mechanism of each is described in dedicated analyses: an analysis of BAM15 as a mitochondrial uncoupler and SLU-PP-332 as an exercise mimetic in the knowledge base.

Frequently asked questions

What is mitochondrial uncoupling?

It is the disconnection of nutrient oxidation from ATP production. The protons that normally return into the mitochondrion through ATP synthase (driving energy production) leak back bypassing it, and the energy of the gradient is dissipated as heat. The mitochondrion burns fuel without storing its energy.

What does the UCP1 protein do?

UCP1 (thermogenin) is a natural proton channel in the mitochondria of brown adipose tissue. It allows protons to return across the membrane bypassing ATP synthase, which leads to the production of heat instead of ATP. This is the physiological mechanism of thermogenesis, activated, among other things, by exposure to cold.

How does brown adipose tissue differ from white?

White adipose tissue stores energy in the form of triglycerides. Brown tissue is specialised in dissipating it as heat — it contains a great many mitochondria rich in UCP1. In adult humans, active brown tissue has been confirmed by PET imaging, mainly in the region of the neck and collarbones.

How does BAM15 differ from DNP?

Both are uncouplers, but DNP is non-selective and has an extremely narrow safety margin (a risk of dangerous hyperthermia). BAM15, in preclinical studies, uncoupled mitochondria without depolarising the cell membrane, which was associated with a more favourable profile. The data relate to animal models; BAM15 is a research reagent.

Is SLU-PP-332 an uncoupler?

Not in the direct sense. SLU-PP-332 is an agonist of ERR receptors — it increases mitochondrial biogenesis and oxidative capacity, rather than dissipating the gradient in existing mitochondria. It is sometimes described as an “exercise mimetic”. This is a separate route to increasing energy expenditure, studied in animal models.

Does exposure to cold activate brown adipose tissue?

In studies, exposure to cold is the classic stimulus that activates brown adipose tissue via the sympathetic nervous system and noradrenaline. This is a well-documented physiological mechanism. This article describes the mechanism at the level of biochemistry — it does not make any recommendations regarding any practices.

What is “proton leak”?

It is the return of protons across the inner mitochondrial membrane bypassing ATP synthase. A certain level of it always occurs in mitochondria and accounts for part of resting oxygen consumption. Adaptive thermogenesis and pharmacological uncouplers act through a regulated or induced increase in this phenomenon.

Summary

• Adaptive thermogenesis is regulated heat production; its mechanism is mitochondrial uncoupling.
• Uncoupling consists in the return of protons into the mitochondrion bypassing ATP synthase — the energy of the gradient is dissipated as heat, and energy expenditure rises.
• The physiological model is brown adipose tissue and the UCP1 protein, activated, among other things, by cold.
• Pharmacological uncouplers have been studied, from the dangerous DNP to targeted compounds: BAM15 (an uncoupler without depolarisation of the plasma membrane) and SLU-PP-332 (an ERR agonist, mitochondrial biogenesis).
• The data on pharmacological compounds come from animal models and in vitro studies; their significance in humans remains the subject of research.

This content is educational in nature and constitutes a review of the published scientific literature in the field of the biochemistry of energy metabolism. BAM15, SLU-PP-332 and the other compounds mentioned are chemical reagents intended solely for laboratory research use (Research Use Only) — they are not medicines, dietary supplements or products for human consumption. The mechanisms and findings described relate for the most part to animal models and in vitro studies; they do not constitute medical advice or a suggestion to use any substance. The classic uncoupler DNP is mentioned solely as a historical and cautionary point of reference — it is a dangerous substance.

References

1. Cannon B, Nedergaard J (2004). Brown adipose tissue: function and physiological significance
2. Kenwood BM et al. (2014). Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane
3. Alexopoulos SJ et al. (2020). Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice
4. Axelrod CL et al. (2021). BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control
5. Billon C et al. (2024). A Synthetic ERR Agonist Alleviates Metabolic Syndrome

Bartosz BartczakPhysiotherapist, Personal Trainer

Physiotherapist with 20 years of clinical experience, graduate of Poznan University of Medical Sciences. Founder of One Peptides and lead author of clinical-perspective content.

See Full Bio ›